Analysis Replimune Plunges as FDA Rejection Forces Drastic Restructuring
Replimune Group Inc. shares cratered after the U.S. Food and Drug Administration delivered a second, definitive rejection of its lead skin cancer therapy, triggering an immediate corporate overhaul and sending...